

SELECTED REFERENCES

Mechanism of Action and Pharmacology

1. Simpson LL (2004): Identification of the Major Steps in Botulinum Toxin Action. *Ann. Rev. Pharmacol.* 44:167-93.
2. Dressler D and Saberi FA (2003): Botulinum Toxin: Mechanisms of Action. *Eur. Neurol.* 53:3-9.
3. Schantz EJ and Johnson EA (1992): Properties and Use of Botulinum Toxin and other Microbial Neurotoxins in Medicine. *Microbiol. Rev.* 56(1):80-99.
4. Brin MF and Aoki KR (2002): Botulinum Toxin Type A: Pharmacology. In: Mayer NH, ed. *Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin*, pp 110-24.
5. Aoki KR (2004): Pharmacology of Botulinum Neurotoxins. *Oper. Tech. Otolaryngol. Head Neck Surg.* 15(2):81-5.
6. Aoki KR (2004): Botulinum Toxin: A Successful Therapeutic Protein. *Current Medicinal Chem.* 11(23):3085-92.

Botulinum Toxin Assays

7. Notermans S and Nagel J (1989): Assays for Botulinum and Tetanus Toxins. In: *Botulinum Neurotoxin and Tetanus Toxin*, Academic Press, Inc, pp 319-31
8. Schantz EJ and Kautter DA (1978): Microbiological Methods: Standardized Assay for Clostridium botulinum Toxins. *J Assoc. Off. Anal. Chem.* 61(1):96-9.
9. Pearce LB, Borodic GE, First ER and MacCallum RD (1994): Measurement of Botulinum Toxin activity: Evaluation of the Lethality Assay. *Toxicol. Appl. Pharmacol.* 128(1):69-77.
10. McLellan K, Gaines Das RE, Ekong TAN and Sesardic D (1996): Therapeutic Botulinum Type A Toxin: Factors Affecting Potency. *Toxicon* 34(9):975-85.
11. Sesardic D, Leung T, and Gaines Das R (2003): Role for standards in assays for botulinum toxins: International collaborative study of three preparations of botulinum type A toxin. *Biologicals* 31(4):265-76.
12. Aoki KR (2001): A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. *Toxicon* 39(12):1815-1820.
13. Aoki KR (2002): Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. *Toxicon* 40(7):923-28.
14. Cichon JV Jr, McCaffrey TV, Litchy WJ and Knops JL (1995): The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. *Laryngoscope* 105(2):144-8.

15. Sesardic D, McLellan K, Ekong TAN and Gaines Das R (1996): Refinement and validation of an alternative bioassay for potency testing of therapeutic Botulinum Type A Toxin. *Pharmacol. Toxicol.* 78(5):283-8.
16. Liu Y, Jones RGA and Sesardic D: Development and use of the mouse phrenic nerve hemidiaphragm assay for botulinum type A toxin. ABS-50a presented at: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins International Conference (Toxins 2005), June 23-25, 2005, Denver, CO.
17. Ekong TAN, Feavers IM and Sesardic D (1997): Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. *Microbiology* 143:3337-3347.
18. Gaines Das RE, Heath AB, Martin H and Sesardic D (1999): Validation of in vitro Assays for Botulinum Toxin: A case study. *Dev Biol. Stand.* 101:267-76.
19. Welch MJ, Purkiss JR and Foster KA (2000): Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. *Toxicon* 38(2):245-58.
20. Purkiss JR, Friis LM, Doward S and Quinn CP (2001): Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. *NeuroToxicology* 22:447-53.
21. Keller JE, Cai F and Neale EA (2003): Uptake of botulinum neurotoxin into cultured neurons. *Biochemistry* 43:526-32.
22. Williams D, Steward LE, Gilmore MA, Okawa Y, Webber JA and Aoki KR: GFP-SNAP25 fluorescence release assay of BoNT proteolytic activity. ABS-83 presented at: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins International Conference (Toxins 2005), June 23-25, 2005, Denver, CO.
23. Gilmore MA, Williams D, Steward LE, Okawa Y, Webber JA, Verhagen MF and Aoki KR: A coupled FRET-fluorescence polarization assay of BoNT proteolytic activity with a fully recombinant substrate. ABS-35 presented at: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins International Conference (Toxins 2005), June 23-25, 2005, Denver, CO.
24. Steward LE, Fernandez-Salas E, Garay PE, Malik S, Lewis RO and Aoki R: A sensitive cell-based fluorescence resonance energy transfer (FRET) assay for botulinum neurotoxins. ABS-76 presented at: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins International Conference (Toxins 2005), June 23-25, 2005, Denver, CO.
25. Fernandez-Salas E, Garay PE, Iverson C, Malik SZ, Steward LE and Aoki KR: Identification of FGFR3 as a putative receptor for botulinum neurotoxin type A uptake in neuronal cells. ABS-29 presented at: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins International Conference (Toxins 2005), June 23-25, 2005, Denver, CO.
26. Ferracci G, Miquelis R, Kozaki S, Seagars M and Leveque C (2005): Synaptic vesicle chips to assay botulinum neurotoxins. *Biochem. J.* 391:659-66.

27. Maruta T, Doimbek BZ, Aoki KR and Atassi MZ (2006): Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: A new assay for blocking and non-blocking antibodies. *J. Neurosci. Meth.* (In press).
28. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER (2006): SV2 is the protein receptor for Botulinum Neurotoxin A. *Scienceexpress*, (on line), 16 March 2006.
29. Mahrhold S, Rummel A, Bigalke H, Davletov B and Binz T (2006): The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. *FEBS* 580:2011-14.